Mycophenolate mofetil for myasthenia gravis: an open-label pilot study.
In an open-label study, 12 patients with refractory MG or who were taking only corticosteroids and required additional immunosuppression received mycophenolate mofetil 1 g twice daily for 6 months. A reduction of three points in a quantified MG score and two points in a manual muscle test or a reduction of 50% in corticosteroid dose defined efficacy. Eight patients improved, beginning after 2 weeks to 2 months. No major side effects were observed.
Ciafaloni
E
E
Division of Neurology, Duke University Medical Center, Durham, NC, USA. ciafa001@mc.duke.edu
Massey
J M
JM
Tucker-Lipscomb
B
B
Sanders
D B
DB
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000188:drug therapy*; D009173:Mycophenolic Acid / Q000008:administration & dosage* / Q000031:analogs & derivatives; D010865:Pilot Projects; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid